Harrow, Inc. (HROW)

Market Cap	1.34B +35.8%
Revenue (ttm)	272.30M +36.4%
Net Income	-5.14M
EPS	-0.14
Shares Out	37.23M
PE Ratio	n/a
Forward PE	78.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	431,845
Open	37.49
Previous Close	37.29
Day's Range	35.50 - 37.70
52-Week Range	21.12 - 54.85
Beta	0.31
Analysts	Strong Buy
Price Target	69.86 (+94.43%)
Earnings Date	May 7, 2026

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 373
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW
• Website: https://www.harrow.com

Financial Performance

In 2025, Harrow's revenue was $272.30 million, an increase of 36.41% compared to the previous year's $199.61 million. Losses were -$5.14 million, -70.60% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price target is $69.86, which is an increase of 94.43% from the latest price.

Price Target

$69.86

(94.43% upside)

Analyst Consensus: Strong Buy